<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948788</url>
  </required_header>
  <id_info>
    <org_study_id>SHR1459-II-201</org_study_id>
    <nct_id>NCT04948788</nct_id>
  </id_info>
  <brief_title>SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I/ II Study of SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for&#xD;
      Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: MTD （Maximum tolerated dose）or RP2D（Recommended Phase II Dose) of SHR1459 and YY-20394;</measure>
    <time_frame>Minimum observation period is 28 days for the maximum dose cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Overall response rate (ORR)</measure>
    <time_frame>8 weeks after last patient first visit (LPFV)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>At every treatment and follow up visit until disease progression. Expected to be for up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>SHR1459 + YY-20394 (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR1459 + YY-20394 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GemOx (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1459 ；YY-20394</intervention_name>
    <description>SHR1459 plus YY-20394</description>
    <arm_group_label>SHR1459 + YY-20394 (Stage 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1459 ；YY-20394</intervention_name>
    <description>SHR1459 plus YY-20394</description>
    <arm_group_label>SHR1459 + YY-20394 (Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine-Oxaliplatin</intervention_name>
    <description>Gemcitabine-Oxaliplatin</description>
    <arm_group_label>GemOx (Stage 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of B-cell NHL such as DLBCL, FL and MCL&#xD;
&#xD;
          2. Patients received at least 2 lines of systemic therapy&#xD;
&#xD;
          3. Previously received anti- CD20 treatment&#xD;
&#xD;
          4. Patients in stage II should also be unsuitable or unwilling to receive allogeneic&#xD;
             hematopoietic stem cell transplantation&#xD;
&#xD;
          5. Patients must have an acceptable organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously treated with PI3K inhibitors or BTK inhibitors&#xD;
&#xD;
          2. Unresolved toxicity of CTCAE grade &gt; 1 from prior anti-lymphoma therapy&#xD;
&#xD;
          3. Chemotherapy or other investigational therapy within 28 days (or 5 times the half-life&#xD;
             time, whichever is shorter) before starting cycle 1&#xD;
&#xD;
          4. Significant concurrent medical disease or condition which according to the&#xD;
             investigators' judgement&#xD;
&#xD;
          5. Active hepatitis B, C or HIV infection&#xD;
&#xD;
          6. Infection requiring treatment 2 weeks prior to the first dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiwei Wang</last_name>
    <phone>021-61053363</phone>
    <email>weiwei.wang@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

